Amyn Hirani, MD
Pulmonary Disease · Marietta, GANPI 1841401940
Payments from drug & device makers
Across 435 payments — averaging $156.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$38K
- Mallinckrodt Enterprises LLC$14K
- Mallinckrodt Hospital Products Inc.$11K
- Boehringer Ingelheim$984
- AstraZeneca$676
- Regeneron Healthcare Solutions, Inc.$485
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$59,37587%
- Travel & lodging$900%
- Food & beverage$8,38512%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 192 | $37,575 |
| Mallinckrodt Enterprises LLC | 13 | $14,055 |
| Mallinckrodt Hospital Products Inc. | 10 | $11,303 |
| Boehringer Ingelheim | 47 | $984 |
| AstraZeneca(2 entities) | 29 | $676 |
| Regeneron Healthcare Solutions, Inc. | 21 | $485 |
| Sanofi | 15 | $431 |
| Grifols USA, LLC | 18 | $391 |
| ANI Pharmaceuticals, Inc. | 15 | $296 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $226 |
| Insmed, Inc. | 5 | $192 |
| Merck | 5 | $126 |
| Johnson & Johnson | 1 | $125 |
| Pulmonx Corporation | 2 | $103 |
| Amgen | 5 | $88 |
| Mylan Specialty L.p. | 4 | $80 |
| Baxter Healthcare | 4 | $76 |
| Genentech USA, Inc. | 4 | $75 |
| Eisai Inc. | 3 | $71 |
| Shire North American Group Inc | 3 | $64 |
| Verona Pharma, Inc. | 3 | $64 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| United Therapeutics Corporation | 2 | $55 |
| Ipsen Biopharmaceuticals, Inc | 2 | $54 |
| AbbVie(2 entities) | 3 | $51 |
| Viatris Specialty LLC | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Nabriva Therapeutics, PLC | 2 | $27 |
| CSL Behring | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Inari Medical, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $16 |
| ADMA Biomanufacturing LLC | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$35,323
- ACTHAR$24,999
- XARELTO$125
- TRELEGY ELLIPTA$121
- IMFINZI$114
How this compares
$67,993 in reported general payments places this provider in the 85th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 375 | $354,187 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 121 | $90,117 |
| NucalaMepolizumab | 22 | $81,424 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $37,306 |
| EliquisApixaban | 39 | $35,481 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $24,869 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $9,991 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 276 | $8,335 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $6,557 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $5,767 |
| Arnuity ElliptaFluticasone Furoate | 21 | $5,051 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $4,613 |
| Ventolin HfaAlbuterol Sulfate | 35 | $3,257 |
| Montelukast Sodium | 290 | $3,201 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $2,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $37,575 | $502,836509 claims |
| AstraZenecaBreztri Aerosphere | $676 | $90,117121 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $984 | $15,75728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Marietta
- Hitendra PatelMarietta$104K
- Jeffrey MichaelsonMarietta$69K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.